p.R72P, PIN3 Ins16bp Polymorphisms of TP53 and CCR5Δ32 in North Indian Breast Cancer Patients |
Guleria, Kamlesh
(Human Cytogenetics Laboratory, Department of Human Genetics, Guru Nanak Dev University)
Sharma, Sarika (Human Cytogenetics Laboratory, Department of Human Genetics, Guru Nanak Dev University) Manjari, Mridu (Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research) Uppal, Manjit Singh (Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research) Singh, Neeti Rajan (Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research) Sambyal, Vasudha (Human Cytogenetics Laboratory, Department of Human Genetics, Guru Nanak Dev University) |
1 | Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol, 8, 275-83. DOI |
2 | Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. Nat Rev Cancer, 2, 594-604. DOI ScienceOn |
3 | Wang-Gohrke S, Becher H, Kreienberg R, et al (2002). Intron 3 16bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics, 12, 269-72. DOI |
4 | Weng CJ, Chien MH, Lin CW, et al (2010). Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol, 46, 767-72. DOI |
5 | Weston A, Pan CF, Ksieski HB, et al (1997). p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev, 6, 105-12. |
6 | Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. DOI ScienceOn |
7 | Wu X, Zhao H, Amos CI, et al (2002). p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst, 94, 681-90. DOI ScienceOn |
8 | Wilson J, Balkwill F (2002). The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol, 12, 113-20. DOI |
9 | Woelfelschneider A, Popanda O, Lilla C, et al (2008). A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis, 29, 1758-64. DOI |
10 | Xu Y, Yao L, Ouyang T, et al (2005). p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Clin Cancer Res, 11, 7328-33. DOI |
11 | Xu Y, Yao L, Zhao A, et al (2008). Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer, 122, 2761-6. DOI |
12 | Yang X, Ahmad T, Gogus F, et al (2004). Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behçet's disease. Eur J Immunogenet, 31, 11-4. DOI |
13 | Zafiropoulos A, Crikas N, Passam AM, et al (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet, 41, e59. DOI |
14 | Zheng B, Wiklund F, Gharizadeh B, et al (2006). Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res, 26, 3669-74. |
15 | Zhu ZZ, Wang AZ, Jia HR, et al (2007). Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol, 37, 385-90. DOI |
16 | Beckman G, Birgander R, Sjalander A, et al (1994). Is p53 polymorphism maintained by natural selection? Hum Hered, 44, 266-70. DOI ScienceOn |
17 | Aizat AA, Shahpudin SN, Mustapha MA, et al (2011). Association of Arg72Pro of P53 polymorphism with colorectal cancer susceptibility risk in Malaysian population. Asian Pac J Cancer Prev, 12, 2909-13. |
18 | Aoki MN, Da Silva do Amaral Herrera AC, Amarante MK, et al (2009). CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med, 23, 429-35. |
19 | Apostolakis S, Baritaki S, Krambovitis E, et al (2005). Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population. J Clin Virol, 34, 310-4. DOI |
20 | Bergamaschi D, Gasco M, Hiller L, et al (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402. DOI ScienceOn |
21 | Cao Z, Song JH, Park YK, et al (2009). The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma, 56, 114-8. DOI |
22 | Bhasin MK, Walter H, Danker-Hopfe H. The Distribution of Genetical, Morphological and Behavioral Traits Among the Peoples on Indian Region. Kamla-Raj Publishers, New Delhi, 1992. |
23 | Bisof V, Salihovic, MP, Narancic NS, et al (2012). The TP53 gene polymorphisms and survival of sporadic breast cancer patients. Med Oncol, 29, 472-8. DOI |
24 | Buyru N, Tigli H, Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol Rep, 10, 711-4. |
25 | Costa S, Pinto D, Pereira D, et al (2008). Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer, 8, 32. DOI |
26 | Fiszer-Maliszewska L, Kazanowska B, Kusnierczyk P, et al (2004). Is p53 intronic variant G13964C associated with predisposition to cancer? J Appl Genet, 44, 547-52. |
27 | De Vecchi G, Verderio P, Pizzamiglio S, et al (2008). The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev, 32, 140-3. DOI |
28 | Dumont P, Leu JI, Della Pietra AC 3rd, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65. DOI ScienceOn |
29 | Faghani M, Ghasemi FM, Nikhbakht M, et al (2011). TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women. Indian J Cancer, 48, 298-302. DOI ScienceOn |
30 | Franekova M, Zubor P, Stanclova A, et al (2007). Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma, 54, 155-61. |
31 | Gemignani F, Moreno V, Landi S, et al (2004). A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23, 1954-6. DOI |
32 | Hamajima N, Takezaki T, Tajima K (2002). Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev, 3, 197-206. |
33 | Hrstka R, Beranek M, Klocova K, et al (2009). Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep, 22, 1205-11. |
34 | Kaimen-Maciel DR, Reiche EM, Brum Souza DG, et al (2007). CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med, 20, 337-44. |
35 | Kazemi M, Salehi Z, Chakosari RJ (2009). TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res, 18, 25-30. DOI |
36 | Khaliq S, Hameed A, Khaliq T, et al (2000). P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test, 4, 23-9. DOI ScienceOn |
37 | Mabrouk I, Baccouche S, El-Abed R, et al (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci, 1010, 764-70. DOI |
38 | Kim JG, Sohn SK, Chae YS, et al (2009). TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol, 64, 355-60. DOI |
39 | Langerod A, Bukholm IR, Bregard A, et al (2002). The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev, 11, 1684-8. |
40 | Luettichau VI, Segerer S, Wechselberger A, et al (2008). A complex pattern of chemokine receptor expression is seen in osteosarcoma. BMC Cancer, 8, 23. DOI |
41 | Majumder PP, Dey B (2001). Absence of the HIV-1 protective Delta ccr5 allele in most ethnic populations of India. Eur J Hum Genet, 9, 794-6. DOI |
42 | Malik MA, Sharma K, Goel S, et al (2011). Association of TP53 intron 3, 16 bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley. Oncol Res, 19, 165-9. DOI |
43 | Manes S, Mira E, Colomer R, et al (2003). CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med, 198, 1381-9. DOI |
44 | Matlashewski GJ, Tuck S, Pim D, et al (1987). Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol, 7, 961-3. |
45 | Mattick JS (1994). Introns: evolution and function. Curr Opin Genet Dev, 4, 823-31. DOI |
46 | Mattick JS (2004). RNA Regulation: a new genetics? Nat Rev Genet, 5, 316. DOI |
47 | Pezeshki A, Sari-Aslani F, Ghaderi A, et al (2006). p53 codon 72 polymorphism in basal cell carcinoma of the skin. Pathol Oncol Res, 12, 29-33. DOI |
48 | Osorio A, Pollan M, Pita G, et al (2008). An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br J Cancer, 99, 974-7. DOI ScienceOn |
49 | Pandith AA, Shah ZA, Khan NP, et al (2010). Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet, 203, 263-8. DOI ScienceOn |
50 | Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92. DOI ScienceOn |
51 | Santos AM, Sousa H, Portela C, et al (2006). TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun, 340, 256-62. DOI |
52 | Runnebaum IB, Tong XW, Konig R, et al (1995). p53- based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet, 345, 994. |
53 | Sameer AS, Shah ZA, Syeed N, et al (2010). TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res, 9, 651-60. DOI ScienceOn |
54 | Samson M, Libert F, Doranz BJ, et al (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382, 722-5. DOI |
55 | Sayeed N, Sameer AS, Abdullah S, et al (2010). A case-control study of TP53 R72P polymorphism in breast cancer patients of ethnic Kashmiri population. World J Oncol, 1, 236-41. |
56 | Siddique MM, Balram C, Fiszer-Maliszewska L, et al (2005). Evidence for selective expression of the p53 codon 72 polymorphs: Implications in cancer development. Cancer Epidemiol Biomarkers Prev, 14, 2245-52. DOI |
57 | Sidoti A, D'Angelo R, Rinaldi C, et al (2005). Distribution of the mutated delta 32 allele of the CCR5 gene in a Sicilian population. Int J Immunogenet, 32, 193-8. DOI |
58 | Suspitsin EN, Buslov KG, Grigoriev MY, et al (2003). Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer, 103, 431-3. DOI |
59 | Srivastava A, Pandey SN, Choudhuri G, et al (2008). Polymorphism: Associated with Gallbladder Cancer Susceptibility. Scand J Immunol, 67, 516-22. DOI |
60 | Sullivan A, Syed N, Gasco M, et al (2004). Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene, 23, 3328-37. DOI |
61 | Takiar R, Nadayil D, Nandakumar A (2010). Projections of Number of Cancer Cases in India (2010-2020) by Cancer Groups. Asian Pac J Cancer Prev, 11, 1045-9. |
62 | Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100. |
63 | Vannini I, Zoli W, Tesei A, et al (2008). Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol, 29, 145-51. DOI |
64 | Tommiska J, Eerola H, Heinonen M, et al (2005). Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res, 11, 5098-103. DOI |
65 | Toyama T, Zhang Z, Nishio M, et al (2007). Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res, 9, R34. DOI |
66 | van Deventer HW, O'Connor W, Brickey WJ, et al (2005). C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res, 65, 3374-9. |
67 | Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature, 408, 307-10. DOI ScienceOn |